Literature DB >> 18212649

Using a cost-benefit analysis to estimate outcomes of a clinical treatment guideline: testing theBrain Trauma Foundation guidelines for the treatment of severe traumatic brain injury.

Mark Faul1, Marlena M Wald, Wesley Rutland-Brown, Ernest E Sullivent, Richard W Sattin.   

Abstract

BACKGROUND: A decade after promulgation of treatment guidelines by the Brain Trauma Foundation (BTF), few studies exist that examine the application of these guidelines for severe traumatic brain injury (TBI) patients. These studies have reported both cost savings and reduced mortality. MATERIALS: We projected the results of previous studies of BTF guideline adoption to estimate the impact of widespread adoption across the United States. We used surveillance systems and national surveys to estimate the number of severely injured TBI patients and compared the lifetime costs of BTF adoption to the current state of treatment.
RESULTS: After examining the health outcomes and costs, we estimated that a substantial savings in annual medical costs ($262 million), annual rehabilitation costs ($43 million) and lifetime societal costs ($3.84 billion) would be achieved if treatment guidelines were used more routinely. Implementation costs were estimated to be $61 million. The net savings were primarily because of better health outcomes and a decreased burden on lifetime social support systems. We also estimate that mortality would be reduced by 3,607 lives if the guidelines were followed.
CONCLUSIONS: Widespread adoption of the BTF guidelines for the treatment of severe TBI would result in substantial savings in costs and lives. The majority of cost savings are societal costs. Further validation work to identify the most effective aspects of the BTF guidelines is warranted.

Entities:  

Mesh:

Year:  2007        PMID: 18212649     DOI: 10.1097/TA.0b013e3181493080

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  61 in total

1.  Reducing cancer costs and improving quality through collaboration with payers: a proposal from the Florida society of clinical oncology.

Authors:  Thomas Marsland; Gerald Robbins; Alan Marks; Robert Cassell; Dorothy Green Philips; Kristen King
Journal:  J Oncol Pract       Date:  2010-09       Impact factor: 3.840

2.  Quality of care indicators for the rehabilitation of children with traumatic brain injury.

Authors:  Frederick P Rivara; Stephanie K Ennis; Rita Mangione-Smith; Ellen J MacKenzie; Kenneth M Jaffe
Journal:  Arch Phys Med Rehabil       Date:  2012-01-26       Impact factor: 3.966

Review 3.  Hypothermia following pediatric traumatic brain injury.

Authors:  P David Adelson
Journal:  J Neurotrauma       Date:  2009-03       Impact factor: 5.269

4.  Health and economic burden of traumatic brain injury: Missouri, 2001-2005.

Authors:  Noaman A Kayani; Sherri Homan; Shumei Yun; Bao Ping Zhu
Journal:  Public Health Rep       Date:  2009 Jul-Aug       Impact factor: 2.792

5.  Progenitor cells as remote "bioreactors": neuroprotection via modulation of the systemic inflammatory response.

Authors:  Peter A Walker; Phillip A Letourneau; Supinder Bedi; Shinil K Shah; Fernando Jimenez; Charles S Cox
Journal:  World J Stem Cells       Date:  2011-02-26       Impact factor: 5.326

6.  Effectiveness of seatbelts in mitigating traumatic brain injury severity.

Authors:  Latha Ganti; Aakash N Bodhit; Yasamin Daneshvar; Kelsey Hatchitt; Sudeep Kuchibhotla; Christa Pulvino; Sarah W Ayala; Keith R Peters
Journal:  World J Emerg Med       Date:  2021

7.  Direct intrathecal implantation of mesenchymal stromal cells leads to enhanced neuroprotection via an NFkappaB-mediated increase in interleukin-6 production.

Authors:  Peter A Walker; Matthew T Harting; Fernando Jimenez; Shinil K Shah; Shibani Pati; Pramod K Dash; Charles S Cox
Journal:  Stem Cells Dev       Date:  2010-06       Impact factor: 3.272

8.  Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic cell swelling and GFAP, V1aR and AQP4 expression after focal traumatic brain injury.

Authors:  Christina R Marmarou; Xiuyin Liang; Naqeeb H Abidi; Shanaz Parveen; Keisuke Taya; Scott C Henderson; Harold F Young; Aristotelis S Filippidis; Clive M Baumgarten
Journal:  Brain Res       Date:  2014-06-13       Impact factor: 3.252

9.  Knowledge translation of the American College of Emergency Physicians' clinical policy on syncope using computerized clinical decision support.

Authors:  Edward R Melnick; Nicholas G Genes; Neal K Chawla; Meredith Akerman; Kevin M Baumlin; Andy Jagoda
Journal:  Int J Emerg Med       Date:  2010-06-01

10.  Progenitor cell therapy for the treatment of central nervous system injury: a review of the state of current clinical trials.

Authors:  Peter A Walker; Matthew T Harting; Shinil K Shah; Mary-Clare Day; Ramy El Khoury; Sean I Savitz; James Baumgartner; Charles S Cox
Journal:  Stem Cells Int       Date:  2010-07-20       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.